Learning from the COVID-19 Pandemic: Next-generation universal vaccines and immunotherapeutic research

Abstract

Learning from the COVID-19 Pandemic: Next-generation universal vaccines and immunotherapeutic research With the COVID-19 pandemic behind us, we need to focus on universal vaccines and/or immunotherapeutic strategies and technologies to tackle ongoing endemic infections with SARS-CoV2, influenza, and RSV and prepare for any future pandemics, says Dr Babita Agrawal. In the 21st century, we have witnessed the emergence of respiratory infections with pandemic potential, like corona and influenza viruses, on multiple occasions. Due to the global dissemination of one such coronavirus, SARS-CoV2 (severe acute respiratory syndrome-coronavirus type-2), the World Health Organization (WHO) declared a worldwide pandemic in March 2020. The global public health emergency was declared over in May 2023 by the WHO, but infections with variants of SARS-CoV2 continue to evolve and cause infections worldwide. (1) Besides public health measures, developing, approving, and implementing vaccines against SARS-CoV2 have helped mitigate and end the pandemic. However, the existing vaccines against SARS-CoV2 are not preventive, do not induce mucosal immunity, induce only short-term protection and are ineffective against emerging variants, thereby requiring regular updated boosters.